3.06
-0.11 (-3.47%)
| Penutupan Terdahulu | 3.17 |
| Jumlah Dagangan | 425,307 |
| Harga / Buku (P/B) | 1.48 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -11,193.25% |
| EPS Cair (TTM) | -3.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -62.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 31.69% |
| Nisbah Semasa (MRQ) | 1.69 |
| Aliran Tunai Operasi (OCF TTM) | -31.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.08 M |
| Pulangan Atas Aset (ROA TTM) | -48.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -92.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | SAB Biotherapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.07 |
|
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.02% |
| % Dimiliki oleh Institusi | 23.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Caligan Partners Lp | 30 Jun 2026 | 7,967,207 |
| Commodore Capital Lp | 30 Jun 2026 | 2,870,000 |
| Spruce Street Capital Lp | 30 Jun 2026 | 2,198,502 |
| Sessa Capital Im, L.P. | 30 Jun 2026 | 2,198,457 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |